Ratings Lucid Diagnostics Inc.

Equities

LUCD

US54948X1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
0.905 ^USD	+1.69%		-4.17%	-35.82%

May. 13	Transcript : Lucid Diagnostics Inc., Q1 2024 Earnings Call, May 13, 2024
May. 13	Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
LUCID DIAGNOSTICS INC.	-35.82%	45.08M	-
SHOCKWAVE MEDICAL, INC.	+73.24%	12.39B	B-
PENUMBRA, INC.	-19.09%	7.89B	C+
MASIMO CORPORATION	+5.88%	6.59B	C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+13.24%	5.43B	D+
APT MEDICAL INC.	+38.48%	4.96B	-
GETINGE AB	-17.30%	4.72B	B
ASAHI INTECC CO., LTD.	-19.78%	4.02B	B-
INARI MEDICAL, INC.	-29.53%	2.66B	C
NOVOCURE LIMITED	+47.29%	2.37B	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes